ClinicalTrials.gov
ClinicalTrials.gov Menu

Plasma Cystatin C and Acute Kidney Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01652755
Recruitment Status : Unknown
Verified August 2012 by Hongying Ni, Jinhua Central Hospital.
Recruitment status was:  Recruiting
First Posted : July 30, 2012
Last Update Posted : August 6, 2012
Sponsor:
Information provided by (Responsible Party):
Hongying Ni, Jinhua Central Hospital

Brief Summary:
To evaluate the utility of plasma cystatin C(pCysC) as a predictive and diagnostic marker of acute kidney injury(AKI) in patients undergone cardiopulmonary bypass surgery.

Condition or disease
Acute Kidney Injury

Detailed Description:
This is a prospective AKI observational study in patients undergone cardiopulmonary bypass surgery. pCysC and plasma creatine will be measured at entry to ICU.AKI was defined as 50% increase in plasma creatine above baseline.The predictive and diagnostic performance of pCysC will be assessed from area under receiver operator characteristic curve(AUC) and odds ratio(OR).

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery
Study Start Date : April 2011
Estimated Primary Completion Date : May 2013
Estimated Study Completion Date : May 2013

Group/Cohort
AKI group
patients with AKI after cardiopulmonary bypass surgery
non-AKI group
patients without AKI during study period




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients undergone cardiopulmonary bypass surgery
Criteria

Inclusion Criteria:

  • patients with CPB and admitted to ICU

Exclusion Criteria:

  • patients with the age >80 or <18 years
  • with preexisting renal dysfunction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01652755


Contacts
Contact: Hongying Ni, MM 86 ext 57982552629 nihongying2@163.com

Locations
China, Zhejiang
Jinhua central hospital Recruiting
Jinhua, Zhejiang, China, 321000
Contact: Hongying Ni, MM    86 ext 57982552629    nihongying2@163.com   
Principal Investigator: Hongying Ni, MM         
Sponsors and Collaborators
Jinhua Central Hospital
Investigators
Study Chair: Hongying Ni, MM Jinhua Municipal Central Hospital

Responsible Party: Hongying Ni, Department vice director, Jinhua Central Hospital
ClinicalTrials.gov Identifier: NCT01652755     History of Changes
Other Study ID Numbers: N-H-Y
First Posted: July 30, 2012    Key Record Dates
Last Update Posted: August 6, 2012
Last Verified: August 2012

Keywords provided by Hongying Ni, Jinhua Central Hospital:
cystatin C,acute kidney injury,

Additional relevant MeSH terms:
Wounds and Injuries
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Cystatins
Cysteine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action